Cancer-COVID Surgery

26 марта 2020

Dear Colleague,

Thank you very much for registering your interest to participate in CovidSurg. We appreciate that this is a difficult time for many both professionally and personally, so we greatly appreciate your support. Over 2300 clinicians across 800 hospitals in 101 countries have registered to participate. We hope that by collaborating we will be able to rapidly collect high-quality data to improve our patients’ care.

The CovidSurg platform includes the following studies:

CovidSurg cohort study

This will capture all patients who undergo surgery and have COVID-19 infection either at the time of surgery or within 30 days of surgery. Centres can choose to include only children, only adults, or both children and adults. Data can be collected either retrospectively or prospectively. The protocol and data collection sheet are attached. Up-to-date study documentation is available at any time from our website: https://globalsurg.org/covidsurg/.

Cancer-CovidSurg

This has been designed in response to feedback from collaborators. It will include all patients diagnosed with tumours that would normally require surgery (both operated and non-operated patients, COVID +ve and COVID -ve are included). Cancer-CovidSurg will determine (i) the frequency of hospital-acquired COVID-19 infection in elective surgery; (ii) the impact on COVID-19 infection on outcomes; (iii) delays to elective cancer surgery caused by the pandemic and consequent impact on oncological outcomes. Participating centres will be able to choose to collect data on one or more of the following patient groups: colorectal cancer, oesophagogastric cancer. Further cancer types will join the study in the near future. The protocol and data collection sheet are attached. Up-to-date study documentation is available at any time from our website: https://globalsurg.org/cancercovidsurg/.

How to join

CovidSurg Cohort Study and CovidSurg-Cancer will run in parallel using the same REDCap database. It is preferable to register both studies under the same study approval. Next steps:

1. Liaise with colleagues at your hospital and identify a local Principal Investigator. The CovidSurg and each tumour type included in CovidSurg-Cancer studies can have different PIs. PIs should be consultant/attendings who will take responsibility for study conduct at your hospital.

2. Build a team in your hospital to identify eligible patients and collect data. In particular, as the CovidSurg cohort study includes any type of surgery, consider who you need to involve to identify and capture patients across all specialties. Identify one individual for CovidSurg and one individual for each tumour type you are including in CovidSurg-Cancer who will be responsible for data upload to REDCap. There are no limits on the number of collaborators per hospital.

3. Once you have identified Principal Investigators and REDCap users, please submit their details to us using this short form: https://globalsurgery.redcap.bham.ac.uk/surveys/?s=P4TYA89NXA. We will then be able to issue a REDCap login to your team.

4. Apply for local study approval. Please visit our website https://globalsurg.org/covidsurgcohortstudy/ for guidance and sample documentation for approvals in Germany, Italy, Norway, Portugal, Spain, UK, USA.

5. Prior to formal local study approval, if permitted, you can prospectively collect data using the hard copy case report forms (please find attached). No data should be uploaded to the REDCap database until study approval is confirmed.

6. Co-investigators at your hospital should register their details at http://tiny.cc/covidsurg so that we can keep in touch. A formal authorship list will be collected from each centre at the end of the study.

If you have any questions, please get in touch with us at: covidsurg@contacts.bham.ac.uk.

We look forward to collaborating with you. Thank you for your support.

Best wishes,

Rohan Gujjuri

On behalf of the CovidSurg Collaborative

* Cancer-CovidSurg. Study Protocol V1.0 Скачать в формате DOC